Impact of Baseline BMI on Glycemic Control and Weight Change with Metformin Monotherapy in Chinese Type 2 Diabetes Patients: Phase IV Open-Label Trial

Open Access

Peer-reviewed

Research Article

Linong Ji ,

* E-mail: jiln@bjmu.edu.cn

Affiliation Department of Endocrinology and Metabolism, Peking University People’s Hospital, Beijing, China
⨯
Hongmei Li,

Affiliation Clinical Research, China Research & Development, Sino-American Shanghai Squibb Pharmaceutical Ltd, Shanghai, China
⨯
Xiaohui Guo,

Affiliation Department of Endocrinology, Peking University First Hospital, Beijing, China
⨯
Yan Li,

Affiliation Department of Endocrinology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
⨯
Renming Hu,

Affiliation Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
⨯
Zhengying Zhu

Affiliation Clinical Research, China Research & Development, Bristol-Myers Squibb, Shanghai, China
⨯

Reader Comments (0)

Body mass index
Is the Subject Area "Body mass index" applicable to this article?

Thanks for your feedback.
Obesity
Is the Subject Area "Obesity" applicable to this article?

Thanks for your feedback.
Overweight
Is the Subject Area "Overweight" applicable to this article?

Thanks for your feedback.
HbA1c
Is the Subject Area "HbA1c" applicable to this article?

Thanks for your feedback.
Type 2 diabetes
Is the Subject Area "Type 2 diabetes" applicable to this article?

Thanks for your feedback.
Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.
Body weight
Is the Subject Area "Body weight" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.